Supplementary Online Content
`Wang C, Graham DJ, Kane RC, et al. Comparative Risk of anaphylactic reactions
`associated with intravenous iron products. JAMA. doi:10.1001/jama.2015.15572.
`
`eTable 1. Average Number of Administrations to Reach a Cumulative Dose of 1000mg of Iron Repletion
`
`eTable 2. Baseline Characteristics at Incidence for Patients Receiving IV Iron
`
`eTable 3. Risk of Anaphylaxis at First Administration for Incident Users within Two-Days of IV Iron
`Administration
`
`eTable 4. Risk of Death or Anaphylaxis on the Date of First IV Iron Administration for Incident IV Iron Users
`
`eTable 5. Risk of Anaphylaxis Restricted to Criteria A or B Only at First Administration for Incident IV Iron
`Users
`
`eTable 6. Risk of Anaphylaxis at First Administration for Incident IV Iron Users in Part D Enrolled Population
`
`eTable 7. Risk of Anaphylaxis at First Administration for Incident IV Iron Users (without J3490 code during 06/2009-
`12/2009)
`
`eTable 8. Risk of Anaphylaxis at First Administration by IV Iron Products (01/2006 to 03/ 2008) when Iron Dextran
`could be distinguished
`
`eTable 9. The Rate of Anaphylaxis by Daily Dosage Category by IV Iron Products
`
`eFigure 1. The Rate of Anaphylaxis within Two Days by IV Iron Products and Number of Administration
`
`eFigure 2. The rate of Death or Anaphylaxis on Date of IV Iron Administration by IV Iron Products and Number of
`Administrations
`
`eFigure 3. The Rate of Anaphylaxis Restricted to Criteria A or B Only by IV Iron Products and Number of
`Administrations
`
`eFigure 4. The Rate of Anaphylaxis by IV Iron Products and Number of Administrations in Eligible Part D Population
`
`eFigure 5. The Rate of Anaphylaxis by IV Iron Products and Number of Administrations in Eligible Population without
`J3490 During Period when Ferumoxytol was First Launched
`
`eFigure 6. Cumulative Risk of Anaphylaxis by Number of Administration and IV Iron Products
`
`Appendix 1. Anaphylaxis Definition
`
`Appendix 2. International Classification of Disease, 9th edition, Clinical Modification (ICD-9-CM) Codes used to
`define covariates in the study
`
`This supplementary material has been provided by the authors to give readers additional
`information about their work.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 1
`
`

`

`e-Table 1. Average Number of Administrations to Reach a Cumulative Dose of
`1000mg of Iron Repletion
`
`IV Iron Product
`
`# of Administrations*
`
`Recommended Maximum
`Daily Dose
`2.0
`100mg
`Iron Dextran
`7.0
`125mg
`Iron Gluconate
`4.9
`200mg
`Iron Sucrose
`1.9
`510mg
`Ferumoxytol
`*An administration is identified as a single billing claim for an IV iron injection or infusion. The
`actual iron dose in a given administration of iron can differ.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 2
`
`

`

`Baseline Covariates
`
`e-Table 2. Baseline Characteristics at Incidence for Patients Receiving IV Iron
`(2003-2013)
`Iron Dextran
`Iron
`(N =
`Gluconate
`247,500)
`(N = 94,400)
`73.2 (11.3)
`73.4 (11.8)
`0
`
`Iron Sucrose
`(N =
`264,166)
`73.8 (11.5)
`0
`
`0
`
`Ferumoxytol
`(N = 82,117)
`
`75.3 (10.5)
`0
`
`Age Mean(SD)
`Gender
`Male
`Female
`Race
`White
`Black
`Asian
`Hispanic
`Other/Unknown
`Regions
`Northeast
`Midwest
`South
`West
`Other
`Indications
`Anemia - CKD
`Anemia - GI/GU Bleeding
`Anemia - Other
`Conditions
`Asthma
`COPD
`Coronary Heart Disease
`Depression
`Drug Allergy
`Food Allergy
`Hypertension
`With Part D Enrollment*
`
`36.9%
`63.1%
`
`83.3%
`12.3%
`0.9%
`2.0%
`1.5%
`
`23.0%
`22.2%
`40.3%
`14.0%
`0.5%
`
`42.6%
`18.2%
`39.3%
`
`13.9%
`30.4%
`46.6%
`17.1%
`6.5%
`0.4%
`87.4%
`Iron
`Gluconate
`(N = 37,614)
`
`
`
`
`Concomitant Medications
`NSAIDs
`5%
`5%
`6%
`7%
`Antibiotics
`2%
`3%
`2%
`2%
`Beta-blockers
`43%
`41%
`38%
`33%
`ACE Inhibitors
`25%
`25%
`24%
`25%
`*Note: Data on concomitant medications were only collected for the subset of beneficiaries who were
`enrolled in Medicare Part D (prescription drugs) in 2007- 2013 for the six months prior to index date.
`
`33.7%
`66.3%
`
`86.9%
`9.6%
`0.7%
`1.7%
`1.2%
`
`10.5%
`20.5%
`54.6%
`14.2%
`0.2%
`
`21.5%
`21.7%
`56.8%
`
`13.4%
`29.2%
`41.0%
`16.8%
`6.5%
`0.4%
`82.7%
`Iron Dextran
`(N = 83,627)
`
`37.8%
`62.2%
`
`85.8%
`10.3%
`0.9%
`1.5%
`1.5%
`
`20.2%
`30.9%
`34.1%
`14.7%
`0.2%
`
`54.5%
`14.0%
`31.5%
`
`13.5%
`30.1%
`47.1%
`17.8%
`7.2%
`0.4%
`89.8%
`Iron Sucrose
`(N = 127,472)
`
`39.4%
`60.6%
`
`84.1%
`11.7%
`1.1%
`1.4%
`1.6%
`
`14.2%
`20.9%
`50.7%
`14.1%
`0.2%
`
`59.9%
`11.9%
`28.2%
`
`13.6%
`29.7%
`47.1%
`17.7%
`10.0%
`0.6%
`91.6%
`Ferumoxytol
`(N = 46,046)
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 3
`
`

`

`Sensitivity Analysis Results
`
`e-Table 3. Risk of Anaphylaxis at First Administration for Incident Users within
`Two-Days of IV Iron Administration
`
`IV Iron
`
`2003-2013
`
`2010 to 2013
`
`Iron
`Sucrose
`
`48
`
`Iron
`Dextra
`n
`175
`
`Iron
`Gluconat
`e
`39
`
`Iron
`Sucrose
`
`Ferumoxyto
`l
`
`21
`
`31
`
`Iron
`Dextra
`n
`69
`
`Iron
`Gluconat
`e
`18
`
`264,166
`
`18.2
`(13.5,
`24.3)
`
`Referenc
`e
`
`247,50
`0
`
`70.7
`(60.8,
`82.2)
`
`3.6
`(2.5,
`5.2)
`
`94,400
`
`134,836
`
`82,117
`
`77,935
`
`34,029
`
`41.3
` (29.8,
`57.1)
`
`15.6
`(9.9,
`24.3)
`
`37.8
`(26.1, 54.3)
`
`2.2
`(1.4, 3.5)
`
`Referenc
`e
`
`2.5
`(1.3, 4.8)
`
`88.5
`(69.4,
`112.7)
`
`5.4
` (3.0,
`9.8)
`
`52.9
`(32.3,
`85.4)
`
`3.3
`(1.6, 7.0)
`
`#
`Anaphylaxi
`s Cases
`# New
`Users
`
`Rate per
`100,000
`persons
`(95% CI)
`Adjusted
`Odds Ratio
`(95% CI)*
`
`p-value**
`
`
`
`<0.001
`
`<0.001
`
`
`
`0.004
`
`<0.001
`
`<0.001
`
`*: adjusted for age, indication, CHD, hypertension.
`**: P value adjusted for multiple comparisons.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 4
`
`

`

`e-Figure 1.
`
`
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 5
`
`

`

`e-Table 4. Risk of Death or Anaphylaxis on the Date of First IV Iron Administration
`for Incident IV Iron Users
`
`IV Iron
`
`2003-2013
`
`2010 to 2013
`
`Iron
`Sucrose
`
`64
`
`Iron
`Dextra
`n
`177
`
`Iron
`Gluconat
`e
`45
`
`Iron
`Sucrose
`
`Ferumoxyto
`l
`
`33
`
`34
`
`Iron
`Dextra
`n
`69
`
`Iron
`Gluconat
`e
`18
`
`# Death or
`Anaphylaxi
`s Cases
`
`# New
`Users
`
`264,166
`
`247,50
`0
`
`94,400
`
`134,836
`
`82,117
`
`77,935
`
`34,029
`
`Rate per
`100,000
`persons
`(95% CI)
`Adjusted
`Odds Ratio
`(95% CI)*
`
`24.2
`(18.7,
`30.9)
`
`Referenc
`e
`
`71.5
`(61.4,
`82.9)
`
`2.8
`(2.0,
`3.9)
`
`47.7
`(34.8,
`63.8)
`
`24.5
`(16.8,
`34.4)
`
`41.4
`(28.7, 57.9)
`
`1.9
`(1.2, 2.9)
`
`Referenc
`e
`
`1.7
` (0.9, 3.0)
`
`88.5
`(68.9,
`112.0)
`
`3.7
` (2.2,
`6.1)
`
`52.9
`(31.3,
`83.6)
`
`2.2
` (1.1, 4.3)
`
`p-value**
`
`
`
`<0.001
`
`0.00
`
`
`
`0.08
`
`<0.001
`
`0.024
`
`*: adjusted for age, indication, CHD, hypertension.
`**: P value adjusted for multiple comparisons.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 6
`
`

`

`e-Figure 2.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 7
`
`

`

`e-Table 5. Risk of Anaphylaxis Restricted to Criteria A or B Only at First
`Administration for Incident IV Iron Users
`
`IV Iron
`
`2003-2013
`
`2010 to 2013
`
`Iron
`Sucrose
`
`36
`
`Iron
`Dextra
`n
`157
`
`Iron
`Gluconat
`e
`26
`
`Iron
`Sucrose
`
`Ferumoxyto
`l
`
`15
`
`21
`
`Iron
`Dextra
`n
`58
`
`Iron
`Gluconat
`e
`9
`
`#
`Anaphylaxi
`s Cases
`
`# New
`Users
`
`264,166
`
`247,50
`0
`
`94,400
`
`134,836
`
`82,117
`
`77,935
`
`34,029
`
`Rate per
`100,000
`persons
`(95% CI)
`Adjusted
`Odds Ratio
`(95% CI)*
`
`13.6
`(9.7,
`19.1)
`
`Referenc
`e
`
`63.4
`(54.1,
`74.4)
`
`4.3
`(2.8,
`6.5)
`
`27.5
`(18.4,
`41.0)
`
`11.1
`(6.5,
`18.8)
`
`25.6
`(16.2, 39.8)
`
`2.0
`(1.1, 3.4)
`
`Referenc
`e
`
`2.4
`(1.1, 5.2)
`
`74.4
`(57,
`96.9)
`
`6.3
`(3.2,
`12.6)
`
`26.4
`(12.9,
`52.2)
`
`2.3
`(0.9, 6.2)
`
`p-value**
`
`
`
`<0.001
`
`0.02
`
`
`
`0.03
`
`<0.001
`
`0.116
`
`*: adjusted for age, indication, CHD, hypertension.
`**: P value adjusted for multiple comparisons.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 8
`
`

`

`e-Figure 3.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 9
`
`

`

`e-Table 6. Risk of Anaphylaxis at First Administration for Incident IV Iron Users in
`Part D Enrolled Population
`
`IV Iron
`
`2003-2013
`
`2010 to 2013
`
`Iron
`Sucrose
`
`20
`
`Iron
`Dextra
`n
`59
`
`Iron
`Gluconat
`e
`11
`
`Iron
`Sucrose
`
`Ferumoxyto
`l
`
`11
`
`15
`
`Iron
`Dextra
`n
`45
`
`Iron
`Gluconat
`e
`8
`
`127,472
`
`83,627
`
`37,614
`
`80,127
`
`46,046
`
`45,313
`
`20,348
`
`#
`Anaphylaxi
`s Cases
`
`# New
`Users
`
`Rate per
`100,000
`persons
`(95% CI)
`Adjusted
`Odds Ratio
`(95% CI)*
`
`15.7
`(9.8,
`24.7)
`
`Referenc
`e
`
`70.6
`(54.2,
`91.7)
`
`4.2
`(2.3,
`7.6)
`
`29.2
`(15.4,
`54.1)
`
`13.7
`(7.2,
`25.4)
`
`32.6
`(18.9, 55.1)
`
`1.8
`(0.8, 4.2)
`
`Referenc
`e
`
`2.4
`(1.0, 6.2)
`
`99.3
`(73.3,
`134.1)
`
`6.7
`(3.0,
`14.9)
`
`39.3
`(18.3,
`80.8)
`
`2.7
`(0.9, 8.1)
`
`p-value**
`
`
`
`<0.001
`
`0.20
`
`
`
`0.06
`
`<0.001
`
`0.075
`
`*: adjusted for age, indication, CHD, hypertension, antibiotics, ACE inhibitors, beta-blockers.
`**: P value adjusted for multiple comparisons.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 10
`
`

`

`e-Figure 4.
`
`
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 11
`
`

`

`e-Table 7. Risk of Anaphylaxis at First Administration for Incident IV Iron Users
`(without J3490 code during 06/2009-12/2009)
`
`IV Iron
`
`2003-2013
`
`2010 to 2013
`
`Iron
`Sucrose
`
`Iron
`Dextran
`
`Iron
`Gluconate
`
`Iron
`Sucrose
`
`Ferumoxytol
`
`Iron
`Dextran
`
`Iron
`Gluconate
`
`45
`
`166
`
`34
`
`21
`
`28
`
`66
`
`16
`
`263,299
`
`246,480
`
`94,054
`
`134,427
`
`81,569
`
`77,641
`
`33,897
`
`17.1
`(12.6,
`23.1)
`
`67.3
`(57.7,
`78.6)
`
`36.1
`(25.4,
`51.1)
`
`15.6
`(9.9, 24.3)
`
`34.3
`(23.3, 50.3)
`
`85.0
`(66.3,
`108.8)
`
`47.2
`(27.9,
`78.5)
`
`Reference 3.6 (2.5,
`5.3)
`
`2.0 (1.2,
`3.4)
`
`Reference 2.2 (1.1, 4.4) 5.2 (2.9,
`9.4)
`
`2.9 (1.4,
`6.4)
`
`
`
`<0.001
`
`<0.001
`
`
`
`0.01
`
`<0.001
`
`<0.001
`
`# APH
`Cases
`
`# New
`Users
`
`Rate per
`100,000
`persons
`(95% CI)
`Adjusted
`Odds
`Ratio
`(95%
`CI)*
`p-
`value**
`
`*: adjusted for age, indication, CHD, hypertension.
`**: P value adjusted for multiple comparisons.
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 12
`
`

`

`e-Figure 5.
`
`
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 13
`
`

`

`e-Figure 6. Cumulative Risk of Anaphylaxis by Number of Administration and IV Iron
`Products
`
`
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 14
`
`

`

`e-Table 8. Risk of Anaphylaxis at First Administration by IV Iron Products (01/2006
`to 03/ 2008) when Iron Dextran could be distinguished
`
`IV Iron Products
`
`# Anaphylaxis
`
`# Patients
`
`Infed@
`Dexferrum@
`Iron Gluconate
`Iron Sucrose
`
`40
`3
`8
`6
`
`48,772
`5,142
`22,241
`48,828
`
`Rate of Anaphylaxis
`(per 100,000 persons)
`82.0 (59.4, 112.8)
`58.3 (15.1, 185.8)
`36.0 (16.7, 73.9)
`12.3 (5.0, 28.2)
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 15
`
`

`

`e-Table 9. Rate of Anaphylaxis by Daily Dosage Category by IV Iron Products
`
`IV Iron
`Cohort
`
`Daily Dosage
`
`#
`Patients
`
`#
`Anaphylaxis
`
`Rate
`(/100,00
`0
`Persons)
`
`95% CI
`(/100,000
`Persons)
`
`Iron Dextran
`
`Within Recommended Dosage
`(≤100mg)
`100mg < Dosage ≤ 1000mg
`
`109,302
`
`66,075
`
`108
`
`163.5
`
`35
`
`21
`
`3
`
`19
`
`15
`
`9
`
`36
`
`26
`
`2
`
`32.0
`
`30.7
`
`78.6
`
`24.3
`
`92.0
`
`4.6
`
`54.1
`
`32.9
`
`63.1
`
`(134.7,198.
`1)
`(22.6,45.1)
`
`(19.5,47.9)
`
`(20.3,250.1
`)
`(15.1,38.8)
`
`(53.4,155.5
`)
`(2.2,9.0)
`
`(38.4,75.7)
`
`(22.0,49.0)
`
`(10.9,254.0
`)
`
`Iron
`Gluconate
`
`Iron Sucrose
`
`Ferumoxytol
`
`1000mg < Dosage ≤ 2500mg
`
`68,305
`
`Outlier (Dosage > 2500mg)
`
`Within Recommended Dosage (≤
`125mg)
`Above Recommended Dosage
`(>125mg)
`Within Recommended Dosage
`(≤200 mg)
`Above Recommended Dosage
`(>200mg)
`Within Recommended Dosage
`(≤510mg)
`Above Recommended Dosage
`(>510mg)
`
`3,818
`
`78,076
`
`16,308
`
`197,544
`
`66,599
`
`78,944
`
`3,171
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 16
`
`

`

`Appendix I. Anaphylaxis Definition
`
` Criterion A: Encounter with ICD-9 code- 995.0 [other anaphylactic shock] inpatient
`or emergency department encounter
` Criterion B: Encounter with ICD-9 code 995.0 [other anaphylactic shock] outpatient
`encounter PLUS a code for one of the following symptoms/procedures/treatments:
`• bronchospasm (519.11) or
`•
`stridor (786.1) or
`• hypotension (458.9) or
`• epinephrine (J0170 or J0171) or
`•
`injection of diphenhydramine (J1200) or
`• CPR (92950 or 99.60)
` Criterion C: Encounter with ICD-9 code- (995.3 [allergy unspecified] or 995.2 [other
`unspecified adverse effect of drug] or E930-E949 [drugs, medicinal and biological
`substances causing adverse effects in therapeutic use]) inpatient or emergency
`department encounter PLUS a code for one of the following
`symptoms/procedures/treatments:
`• bronchospasm (519.11) or
`•
`stridor (786.1) or
`•
`injection of diphenhydramine (J1200)
`•
`and a code for one of the following symptoms/procedures/treatments
`• hypotension (458.9) or
`• epinephrine (J0170 or J0171) or
`• CPR (92950 or 99.60)
`
`
`Notes: Diagnosis codes in any position are accepted
`All codes must occur on the same day as the IV Iron administration
`Patients must meet at least one of the criteria A-C to count as having anaphylaxis
`
`
`
`
`
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 17
`
`

`

`Appendix II. International Classification of Disease, 9th edition, Clinical
`Modification (ICD 9-CM) codes used to define covariates in the study
`
`Covariates
`
`ICD-9 Codes
`
`CHD
`
`414.x
`
`
`
`Hypertension
`
`401.x, 402.x, 403.x, 404.x, 405.x, 997.91
`
`Indication - Chronic
`Kidney Disease
`
`585.x
`
`Indication –
`Gastrointestinal or
`Genitourinary Bleeding
`
`455.x, 456.0, 456.20, 530.1, 530.7, 530.82, 531.0, 531.1,
`531.2, 531.3, 531.4, 531.5, 531.6, 531.7, 531.9, 532.0,
`532.1, 532.2, 532.3, 532.4, 532.5, 532.6, 532.7, 532.9,
`533.0, 533.1, 533.2, 533.3, 533.4, 533.5, 533.6, 533.7,
`533.9, 534.0, 534.1, 534.2, 534.3, 534.4, 534.5, 534.6,
`534.7, 534.9, 535.00, 535.01, 535.10, 535.11, 535.20,
`535.21, 535.30, 535.31, 535.40, 535.41, 535.50, 535.51,
`535.60, 535.61, 537.83, 562.00, 562.01, 562.02, 562.03,
`562.10, 562.11, 562.12, 562.13, 568.81, 569.3 , 569.85,
`578.0, 578.1, 578.9, 593.81, 599.7, 599.70, 599.71, 599.72,
`623.8, 626.2, 626.6
`
`Indication – Other
`
`218.x, 579.x, 627.0, 627.1, 640.x, 641.x, 642.x, 643.x, 645.x,
`646.x, 647.x, 648.x, 649.x, V22.x, V23.x
`
`Asthma
`
`COPD
`
`Drug Allergy
`
`Food Allergy
`
`493.x
`
`ICD-9 DGN: 491.x, 492.x, 494.x, 496.x
`
`ICD-9 HCPC: 32141, 32491, G8093, G8094
`
`995.27, 692.3, 693.0, V14.x
`
`692.5, 693.1, 995.6, 995.7, V15.01, V15.02, V15.03, V15.04,
`V15.05
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 18
`
`

`

`Appendix III. International Classification of Disease, 9th edition, Clinical
`Modification (ICD 9-CM) HCPCS codes used to define IV Iron exposure
`
`IV Iron
`iron dextran
`
`
`
`
`
`
`iron gluconate
`
`iron sucrose
`
`ferumoxytol
`
`ICD-9 HCPCS
`J1750
`J1751*
`J1752*
`J1760
`J1770
`J1780
`Q4098
`J2915
`
`Description
`Injection, iron dextran, 50 mg
`Injection, iron dextran, 165, 50 mg
`Injection, iron dextran, 267, 50 mg
`Injection, iron dextran, 2 cc
`Injection, iron dextran, 5 cc
`Injection, iron dextran, 10 cc
`Injection, iron dextran, 50 mg
`Injection, sodium ferric gluconate complex in
`sucrose injection, 62.5 mg
`Injection, sodium ferric gluconate complex in
`sucrose injection, 12.5 mg
`Injection, iron sucrose, 20 mg
`Injection, iron sucrose, 1 mg
`Injection, ferumoxytol, for treatment of iron
`deficiency anemia, 1 mg
`Injection, ferumoxytol, for treatment of iron
`deficiency anemia, 1 mg
`*These codes were used to define INFeD (J1751) and Dexferrum (J1752) during the 27
`month period when they were coded differently. These codes were discontinued in
`March 2008.
`
`J2916
`
`J1755
`J1756
`Q0138
`
`Q0139
`
`© 2015 American Medical Association. All rights reserved.
`
`Downloaded From: http://jama.jamanetwork.com/ by Stine Primdahl on 11/19/2015
`
`Pharmacosmos, Exh. 1056, p. 19
`
`